- Home
- OSUR vs CRVS Comparison
OSUR vs CRVS Comparison
Compare OSUR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- CRVS
- Stock Information
- Founded
- OSUR 2000
- CRVS 2014
- Country
- OSUR United States
- CRVS United States
- Employees
- OSUR N/A
- CRVS N/A
- Industry
- OSUR Medical/Dental Instruments
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- CRVS Health Care
- Exchange
- OSUR Nasdaq
- CRVS Nasdaq
- Market Cap
- OSUR 260.3M
- CRVS 257.0M
- IPO Year
- OSUR 1986
- CRVS 2016
- Fundamental
- Price
- OSUR $3.32
- CRVS $3.17
- Analyst Decision
- OSUR Hold
- CRVS Strong Buy
- Analyst Count
- OSUR 2
- CRVS 5
- Target Price
- OSUR $5.50
- CRVS $12.63
- AVG Volume (30 Days)
- OSUR 720.7K
- CRVS 657.7K
- Earning Date
- OSUR 05-07-2025
- CRVS 03-25-2025
- Dividend Yield
- OSUR N/A
- CRVS N/A
- EPS Growth
- OSUR N/A
- CRVS N/A
- EPS
- OSUR N/A
- CRVS N/A
- Revenue
- OSUR $185,827,000.00
- CRVS N/A
- Revenue This Year
- OSUR N/A
- CRVS N/A
- Revenue Next Year
- OSUR $7.46
- CRVS N/A
- P/E Ratio
- OSUR N/A
- CRVS N/A
- Revenue Growth
- OSUR N/A
- CRVS N/A
- 52 Week Low
- OSUR $2.69
- CRVS $1.30
- 52 Week High
- OSUR $6.35
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- OSUR 43.07
- CRVS 27.95
- Support Level
- OSUR $3.34
- CRVS $3.20
- Resistance Level
- OSUR $3.56
- CRVS $3.45
- Average True Range (ATR)
- OSUR 0.16
- CRVS 0.38
- MACD
- OSUR -0.00
- CRVS -0.11
- Stochastic Oscillator
- OSUR 2.17
- CRVS 6.43
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).